Ankylosing spondylitis: evidence for a non-HLA-B*27 protective effect. by van der Linden, S, van der Heijde, D

A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis by Taylor, P, van der Heijde, D, Landewé, R, McCue, S, Cheng, S, Boonen, A

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis by Coates, L, Gossec, L, Ramiro, S, Mease, P, Van Der Heijde, D, Smolen, J, Ritchlin, C, Kavanaugh, A

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial by van der Heijde, D, Luo, M, Matsumoto, A, Mease, P, Torre-Alonso, J, Wordsworth, B, Wong, R, Davis, J

The effect of tofacitinib on residual pain in patients with psoriatic arthritis by Dougados, M, van der Heijde, D, Bingham, CO, Taylor, PC, Fallon, L, Woolcott, J, Brault, Y, Wang, L, Kessouri, M

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-bl... by Ritchlin, CT, Coates, LC, Mease, PJ, van der Heijde, D, Song, J, Jiang, Y, Shawi, M, Kollmeier, AP, Rahman, P

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial. by Van der Heijde, D, Luo, M, Matsumoto, A, Mease, P, Torre-Alonso, J, Wordsworth, P, Wong, R, Davis, J, Grp, A

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J

Improvements in health related quality of life (HRQL) correlate positively with clinical reponses in ankylosing spondylitis (AS) patients - Results from ATLAS by Van der Heijde, D, Luo, M, Davis, J, Zeidler, H, Mease, P, Breban, M, Cantini, F, Westhovens, R, Wordsworth, P, Wong, R, Kupper, H, Revicki, D

Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS. by van der Heijde, D, Luo, M, Wordsworth, P, Mease, P, Reveille, J, Zeidler, H, Breban, M, Westhovens, R, Chmiel, J, Chen, N, Wong, R, Davis, J

Infliximab and methotrexate in the treatment of rheumatoid arthritis by Lipsky, P, Van Der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. by Lipsky, P, van der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

The impact of the presence of autoantibodies against citrullinated, carbamylated and acetylated peptides on radiographic progression in patients with new onset rheumatoid arthritis... by Nijjar, JS, Morton, FR, Bang, H, van der Heijde, D, Gilmour, A, Paterson, C, McInnes, IB, Raza, K, Buckley, C, Scottish Early Rheumatoid Arthritis Inception Cohort Investigators

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’... by Taylor, P, Keystone, E, Van Der Heijde, D, Tanaka, Y, Ishii, T, Emoto, K, Yang, L, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, De Bono, S, Weinblatt, M, Combe, B

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS by Emery, P, Baeten, D, Sieper, J, Braun, J, van der Heijde, D, McInnes, I, Van Laar, J, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Paramarta, I, Bertolino, A, Wright, A, Hueber, W

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Van Laar, J, Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Baricitinib versus placebo or adalimumab in rheumatoid arthritis by Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y